{"id":2863,"date":"2017-01-04T17:50:51","date_gmt":"2017-01-04T17:50:51","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=19420"},"modified":"2017-01-04T17:50:51","modified_gmt":"2017-01-04T17:50:51","slug":"axim-biotech-receives-positive-pk-data-results-canchew-plus-cbd-gum","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/01\/04\/axim-biotech-receives-positive-pk-data-results-canchew-plus-cbd-gum\/","title":{"rendered":"AXIM\u00ae Biotech Receives Positive PK Data Results for CanChew Plus\u00ae CBD Gum"},"content":{"rendered":"

NEW YORK \u2013 Jan. 04, 2017 \u2013<\/b> AXIM<\/span>\u00ae<\/span><\/a> Biotechnologies, Inc. (AXIM<\/span>\u00ae<\/span> Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results on its CanChew Plus\u00ae CBD Gum, and gears up for clinical trial on alleviating the symptom of irritable bowel syndrome (IBS). <\/span><\/p>\n

The single dose study on 10 mg of cannabidiol (CBD) and 30 mg of CBD determined the concentration of CBD in the blood after chewing one CanChew Plus\u00ae Gum for thirty minutes in healthy volunteers. The 30 mg dosage showed excellent results and this data will be used to determine the optimal concentration in the IBS patient trial. <\/span><\/p>\n

\u201cThese results show that excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an easy-to-use solution,\u201d said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM\u00ae Biotech. \u201cWe believe that we can match or improve the bioavailability profile for CBD compared to other delivery systems such as smoking or oral intake. We look forward to entering clinical trial and making available our cannabis-based medicinal solutions to patients suffering from IBS and other gastrointestinal disorders as soon as possible.\u201d<\/span><\/p>\n

\u201cThis data will be essential as we look to enter into a clinical trial to prove the efficacy of CBD for treatment for IBS. We saw through the study that the 30mg dosage of CBD rendered the most favorable results and will use this data to decide the most optimal dosage for patients in the clinical trial.\u201d Anastassov added.<\/p>\n

###<\/p>\n

About AXIM\u00ae<\/strong><\/p>\n

AXIM\u00ae Biotechnologies, Inc. (OTC: <\/span>AXIM<\/span><\/a>) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew\u00ae, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD\/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit <\/span>www.AXIMBiotech.com<\/span><\/a>.<\/span><\/p>\n

About CanChew\u00ae and CanChew Plus\u00ae<\/strong><\/p>\n

CanChew<\/span><\/a>\u00ae is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew\u00ae website include:<\/span><\/p>\n